Phathom Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
Phathom Pharmaceuticals, Inc. (PHAT) filed a Current Report on Form 8-K on January 7, 2026. The filing announces preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025. The company is incorporated in Delaware and trades on The Nasdaq Global Select Market.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The report serves as a notification that these results have been issued in a press release (Exhibit 99.1) but does not contain the data points within the 8-K body itself.
Material Changes
No material changes versus prior periods are detailed in the text of this filing. The document references a press release for the specific operational and financial comparisons.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, risk factors, or details on contingencies and unusual items. These disclosures are expected to be found in the attached press release referenced as Exhibit 99.1.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific Q4 and full-year 2025 financial figures.
- Verify the company's cash runway and burn rate based on the unaudited results.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm if the preliminary results trigger any covenant reviews or debt obligations.